Pipeline news

• Marinus Pharmaceuticals Receives Positive CHMP Opinion for ZTALMY® (ganaxolone) for the Adjunctive Treatment of Seizures Associated With CDKL5 Deficiency Disorder

  26 May 2023

  

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of ZTALMY® (ganaxolone) oral suspension for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients two to 17 years of age. ZTALMY may be continued in patients 18 years of age and older.

• Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Sarah Noonberg, M.D., Ph.D.

  17 May 2023

  

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Sarah Noonberg, M.D., Ph.D., to its Board of Directors.

• Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results

  11 May 2023

  

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the first quarter ended March 31, 2023.

• binx health and Mark Cuban Cost Plus Drug Company Team Up to Make Healthcare More Accessible and Affordable

  24 April 2023

  

  binx health, a healthcare technology and diagnostics company focused on making routine testing convenient, and the Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) are collaborating to increase access to affordable healthcare and necessary medications for patients across the nation. Together, the companies aim to reduce healthcare disparities and inequities. binx health offers online access to testing to diagnose common conditions such as diabetes, heart disease, and sexually transmitted infections (STIs). Through this collaboration, patients can access testing through binx health’s digital platform, binx everywhere, and receive affordable medication through Cost Plus Drugs online prescription program.

• Epic Sciences Announces Medicare Coverage for Breast-Cancer Focused ctDNA Gene Panel

  19 April 2023

  

  Epic Sciences, Inc. announced today that the company’s 56-gene ctDNA panel for genomic profiling of metastatic breast cancer is covered by the MolDX program (administered by Palmetto GBA) that provides coverage under the Medicare program for molecular diagnostic tests performed in our region. This panel is a key component of our comprehensive DefineMBC blood biopsy for metastatic breast cancer.

• Marinus Pharmaceuticals Appoints Marvin H. Johnson, Jr. to its Board of Directors

  18 April 2023

  

  Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Marvin H. Johnson, Jr. to its Board of Directors.

• binx health Further Expands Commercial Team in Support of Point-of-Care National Rollout

  17 April 2023

  

  binx health, a healthcare technology and diagnostics company focused on making routine testing convenient, announces the Company is expanding its commercial organization in response to a growing demand for its FDA-cleared, CLIA-waived, point-of-care (POC) testing platform for chlamydia (CT) and gonorrhea (NG). The binx io is the only molecular POC platform of its kind proven to detect CT and NG in male urine and female vaginal swab samples in about 30 minutes with performance equivalent to the central laboratory.

• Epic Sciences raises $24m in series G financing to continue funding commercialization of DefineMBC

  14 April 2023

  

  Epic Sciences, Inc. (“Epic” or “Epic Sciences”), a privately held diagnostics company, has completed a $24 million Series G which together with its $43 million Series F financing, totals $67 million raised in the last twelve months. The company will use the capital from this additional round of private investment to fund the commercial infrastructure required to commercialize the three component tests of DefineMBC, which together provide a comprehensive blood-based biopsy result for patients with metastatic breast cancer.

• Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome

  22 March 2023

  

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appoMarinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to ganaxolone for the treatment of Lennox-Gastaut syndrome (LGS).intment of Christine Silverstein to its Board of Directors and Audit Committee.

• Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

  07 March 2023

  

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2022.